Shareholder Jackpot? Pharma Stock Proposes 1:10 Split And 1:1 Bonus To Woo Investors; Buy For Twin Treat?

Welcure Drugs & Pharmaceuticals Ltd. is a well-known pharmaceutical firm in India that was founded in 1992 and produces and sells a variety of pharmaceutical formulations. Welcure Drugs & Pharmaceuticals Ltd.'s share price attained Rs 10.58 on the BSE on August 11, 2025, indicating an upward trend trapped in the upper circuit limit for the day with a gain of around 5%. Following the company's announcement of positive financial results for the quarter ending June 30, 2025 (Q1FY26), investors took notice of the record date for the stock split and bonus shares, which sparked the rise.

Welcure Drugs Bonus Shares & Stock Split

"Pursuant to Regulation 29 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), we wish to inform you that a meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited is scheduled on Friday, August 22, 2025, inter alia, to consider the following items: 1. Sub-division (stock split) of the Company's equity shares in the ratio of 1:10 (i.e., one equity share into ten equity shares), subject to approvals as may be required. 2. Issue of Bonus Shares up to 1:1 (i.e., one bonus equity share for every one equity share held), subject to availability of adequate reserves and receipt of requisite approvals," said Welcure Drugs & Pharmaceuticals in a stock exchange filing on Monday.

"These proposals are being considered with the objective of enhancing liquidity, broadbasing shareholding and improving affordability for investors, subject to the Board's decision and subsequent statutory/ shareholder approvals. If approved, the record date(s) and detailed terms, including the sequence and timetable of the corporate actions, will be intimated separately in due course in compliance with SEBI LODR and applicable laws. Further, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct, the trading window for dealing in the Company's securities shall remain closed with immediate effect and will reopen 48 hours after dissemination of the outcome of the aforesaid Board meeting," Welcure Drugs & Pharmaceuticals further informed the stock exchanges on 11th August.

Welcure Drugs Financials

Welcure's revenue from operations increased substantially from Rs 21.21 crores in Q4FY25 to Rs 299.91 crores in Q1FY26 for the quarter ending June 30, 2025, representing a roughly 1300% growth on a Q-o-Q basis. In comparison to the net loss of Rs 0.34 crores in Q1FY25 of the previous year, the firm recorded a net profit of Rs 23.29 crores in Q1FY26. On a quarterly basis, the company's net profit increased by about 830% to Rs 23.29 Cr compared to the net profit of Rs 2.5 crore recorded in Q4FY25, which concluded on March 31, 2025.

In Q1FY26, earnings per share (EPS) were Rs 2.07, up from Rs -0.26 in Q1FY25.

Welcure Drugs Target Price

"Welcure Drugs' stock price is slightly bullish on the Daily charts with strong support at 10. A Daily close above resistance of 10.86 could lead to a target of 11.89 in the near term," commented A R Ramachandran, independent research analyst.

Disclaimer

The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred to as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.